Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 12, 2011, details the results of a special meeting of stockholders held by Jazz Pharmaceuticals, Inc. The primary focus is the approval of a merger agreement with Azur Pharma Limited (to be renamed Jazz Pharmaceuticals plc) and the adoption of new equity incentive plans contingent upon the merger's completion.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It is a corporate governance report regarding a merger and equity plan approvals rather than a financial performance report.
Material Changes and Voting Results
Stockholders voted on five proposals at the special meeting. Based on 35,987,058 shares present (out of 42,157,349 entitled to vote), the results were:
- Proposal 1 (Merger Agreement): Approved. 35,935,843 For; 32,884 Against; 18,331 Abstain.
- Proposal 2 (Executive Compensation): Approved. 26,365,217 For; 9,506,997 Against; 114,844 Abstain.
- Proposal 3 (2011 Equity Incentive Plan): Approved. 21,575,308 For; 14,300,884 Against; 110,866 Abstain.
- Proposal 4 (Restated ESPP): Approved. 30,002,928 For; 5,870,433 Against; 113,697 Abstain.
- Proposal 5 (Distributable Reserves): Approved. 35,948,524 For; 28,679 Against; 9,855 Abstain.
Guidance, Outlook, and Risks
Outlook: The Company expects the merger to close in January 2012, assuming all closing conditions are satisfied or waived. Upon closing, Azur Pharma will be renamed Jazz Pharmaceuticals plc ("New Jazz").
Equity Plans:
- 2011 Plan: Authorizes 5,000,000 New Jazz Ordinary Shares initially, with an annual automatic increase (starting Jan 1, 2013) of the least of 4.5% of outstanding shares, 5,000,000 shares, or a board-determined amount.
- Restated ESPP: Authorizes 560,000 New Jazz Ordinary Shares initially, with an annual automatic increase (starting Jan 1, 2013) of the least of 1.5% of outstanding shares, 1,000,000 shares, or a board-determined amount.
Risks: The filing contains forward-looking statements regarding the merger's consummation and timing. There is no assurance the merger will be completed on the proposed terms or schedule. Risks include the satisfaction of closing conditions and other uncertainties detailed in the Company's Form 10-Q for the quarter ended September 30, 2011.
Investor Verification Checklist
- Verify the final closing date of the merger with Azur Pharma (expected January 2012).
- Confirm the successful reorganization and renaming of Azur Pharma to Jazz Pharmaceuticals plc.
- Review the definitive proxy statement (filed Nov 10, 2011) for full terms of the 2011 Equity Incentive Plan and Restated ESPP.
- Monitor for any updates regarding the satisfaction of closing conditions for the merger.